SureTrader Advertisement
Home > Boards > US Listed > Biotechs >

Rexahn Pharmaceuticals, Inc. (RNN)

RNN RSS Feed
Add RNN Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 6/29/2016 6:08:26 PM - Followers: 183 - Board type: Free - Posts Today: 0



   
 



http://www.rexahn.com/cms/     

http://finance.yahoo.com/q/ks?s=RNN

About

Rexahn’s goal is to be a world leader in the discovery and development of new drugs to treat cancer. By developing compounds which specifically target cancer cells, excluding healthy tissue, Rexahn’s drug candidates may demonstrate increased efficacy and reduced toxicity- efficacy against multiple drug resistant cancer cells and synergism with existing cytotoxic compounds. Utilizing a powerful, multi-faceted discovery engine consisting of small signaling molecule discovery, computational modeling, nanotechnology-based drug targeting and delivery, we believe that we are well on our way to achieving our goal.

Rexahn’s core scientific expertise in the understanding of signal transduction processes involved in cancer cell growth is producing a drug portfolio with significant potential clinical value.
 

Today, our clinical development pipeline consists of three novel compounds:

Archexin® (Phase IIa) a best-in-class compound that blocks both the activated and native forms of Akt1 and has FDA orphan drug designation for the treatment of pancreatic cancer, ovarian cancer, stomach cancer, RCC, and glioblastoma.

RX-3117 (Phase I) a best-in-class compound that inhibits DNA and RNA synthesis, and exhibits high oral bioavailability. In comparison, RX-3117 may have a better safety profile than gemcitabine, the current first-line therapy for pancreatic and other cancers.

SupinoxinTM (RX-5902) (Phase I) a first-in-class small molecule that inhibits the phosphorylated p68 RNA helicase, a protein that plays a key role in cancer growth, progression and metastasis.

These lead clinical drugs are part of a growing oncology drug pipeline that consists of highly differentiated and exciting anti-cancer compounds.

Our strategy is to continue building a significant product pipeline of innovative medicines that we will commercialize on our own or with other pharmaceutical partners. Rexahn’s powerful discovery engine and differentiated product pipeline provide the opportunity for a high value generating biopharmaceutical company- one with the expertise to develop cures for significant diseases of our time.
 

Rexahn Pipeline


 

Management Team



Peter Suzdak, Ph.D.
Chief Executive Officer

Dr. Peter Suzdak joined Rexahn Pharmaceuticals in February 2013. Dr. Suzdak has over 25 years of diverse experience, including several management positions, in the pharmaceutical industry. Most recently, Dr. Suzdak was Chief Scientific Officer of Corridor Pharmaceuticals, a company developing small molecule compounds to treat pulmonary and vascular disorders. Prior to Corridor Pharmacueitcals, he was co-Founder, Chief Executive Officer and Chief Scientific Officer of Cardioxyl Pharmaceuticals, a company focused on therapies for the treatment of cardiovascular disease. Previous to Cardioxyl Pharmaceuticals, he was President and Chief Executive Officer of Artesian Therapeutics, a company engaged in the development of small molecule therapeutics for cardiovascular diseases. Dr. Suzdak’s experience also includes his position as Senior Vice President of Research and Development of Guilford Pharmaceuticals, a company that developed therapeutics and diagnostics for neurological diseases and cancer, and as Director of Neurobiology for Novo Nordisk. Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut.

Rick Soni, MBA
President and Chief Operating Officer

Rick Soni joined Rexahn in 2008 with over 20 years of sales, marketing, product planning and business development experience in the pharmaceutical industry. Prior to joining Rexahn, Mr. Soni held leadership roles at Otsuka America Pharmaceuticals, Inc., with responsibility for commercial development, corporate strategy and execution of licensing and acquisition of therapeutics, diagnostics and medical devices. Previously, Mr. Soni has held a variety of management positions at Novartis and Schering-Plough. Mr. Soni has a BS from the University of Wisconsin-Madison and an MBA from Fairleigh Dickinson University.

Tae Heum (Ted) Jeong, D. Mgt.
Sr. Vice President  and Chief Financial Officer

Dr. Jeong has been Chief Financial Officer of Rexahn Pharmaceuticals since 2002. He oversees all aspects of capital raising, accounting, operations, and corporate development for Rexahn. He is also responsible for investor relations, and played a key role in Rexahn’s 2008 listing on the New York Stock Exchange (NYSE) AMEX. For the past 16 years, he has extensive experience in venture capital and investment banking industry that includes role at Hyundai Venture Investment Corporation where he managed the Biotechnology investment team. Dr. Jeong holds a Doctor of Management from University of Maryland and an M.S. in Finance from Johns Hopkins University




ANALYST COVERAGE
 
Roth Capital Partners, LLC
   Joseph Pantginis, Ph.D.
646-358-1907

jpantginis@roth.com

Maxim Group, LLC
Echo He, MD, Ph.D.
212-895-3718

ehe@maximgrp.com

H. C. Wainwright & Co., LLC
Andrew Fein
212-356-0546

afein@hcwco.com


INVESTOR RELATIONSThe Trout Group LLC
Tricia Truehart
(646) 378-2953
ttruehart@troutgroup.com

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RNN
Current Price
Volume:
Bid Ask Day's Range
SureTrader
RNN News: Why Investors Love These Biotech's Stocks? - Cellectar Biosciences, Xenoport, Rexahn Pharma, and Tesaro 06/29/2016 07:45:00 AM
RNN News: Statement of Changes in Beneficial Ownership (4) 06/10/2016 05:06:03 PM
RNN News: Statement of Changes in Beneficial Ownership (4) 06/10/2016 05:05:37 PM
RNN News: Statement of Changes in Beneficial Ownership (4) 06/10/2016 05:02:11 PM
RNN News: Statement of Changes in Beneficial Ownership (4) 06/10/2016 05:02:11 PM
PostSubject
#3075   green today. good things to come!!! XONEC5 06/29/16 06:08:25 PM
#3074   what joke im out glta CashMoneyNY 06/27/16 09:58:47 AM
#3073   CAN WE GET A PARTY GOING ON HERE?????????????? XONEC5 06/23/16 04:48:34 PM
#3072   flippers killing us here jeez just sell already CashMoneyNY 06/23/16 10:58:39 AM
#3071   HOLD !! ITS GONNA RUN HUGE BIDS AND SLAPS CashMoneyNY 06/22/16 12:19:34 PM
#3070   Ask Is Thin to .31+ glta CashMoneyNY 06/22/16 11:45:35 AM
#3069   Once the flippers get out it will fly CashMoneyNY 06/22/16 11:42:57 AM
#3068   End of day will be interesting glta CashMoneyNY 06/22/16 11:42:15 AM
#3067   its on the move Give it one more chance CashMoneyNY 06/22/16 11:40:48 AM
#3066   Strong Hold Glta Volume is coming CashMoneyNY 06/22/16 11:38:59 AM
#3065   Rexahn Pharmaceuticals, Inc. (RNN) Lifted to Hold at CashMoneyNY 06/21/16 10:21:09 PM
#3064   i honestly thought this stock would hit $1 XONEC5 06/21/16 07:06:08 PM
#3063   its a faulty switch she should be on CashMoneyNY 06/20/16 01:28:02 PM
#3062   Houston, we have a problem! kpisme 06/20/16 01:25:37 PM
#3061   Slap that Ask .30+ Next stop CashMoneyNY 06/20/16 10:13:15 AM
#3060   Ladies and gentleman boys and Girls buckle down CashMoneyNY 06/20/16 10:11:35 AM
#3059   I feel that its bottomed out here it CashMoneyNY 06/20/16 09:47:16 AM
#3058   I have 20k shares averaged at .2998 and XONEC5 06/16/16 08:34:30 PM
#3057   I'm hoping the pps stays low all year Valensio 06/16/16 08:31:25 PM
#3056   you just have to be on the wagon XONEC5 06/16/16 04:52:59 PM
#3055   I suppose it will be quiet for awhile, Valensio 06/16/16 04:09:38 PM
#3054   i was trying to locate people that wanted XONEC5 06/16/16 04:03:12 PM
#3053   Is there anything to talk about or just kpisme 06/16/16 11:03:51 AM
#3052   it is like crickets in this room!!! XONEC5 06/15/16 08:33:03 PM
#3051   ya buck 4 2014/04/23 1.04 1.08 1.01 Spuds McKenz66 05/21/16 02:01:56 PM
#3050   Second half of this year (2016) will provide Theo 05/19/16 09:40:19 AM
#3049   tell me about i bailed ,lost a 100 Spuds McKenz66 05/18/16 07:07:32 PM
#3048   Still waiting for the spike, Did I miss kpisme 05/18/16 03:35:03 PM
#3047   spike coming chart is set Spuds McKenz66 04/26/16 01:04:19 PM
#3046   Nice Volume Here Today. PENNYBUSTER 04/25/16 04:58:30 PM
#3045   so what's bringing the trade volume today? DorianGray 04/25/16 12:41:32 PM
#3044   finance.yahoo.com/news/rexahn-pharmaceuticals-presents-clinical-trial-13020 Theo 04/20/16 09:08:54 AM
#3043   So quiet for this cancer company you can Valensio 04/12/16 11:34:30 AM
#3042   I just found this company due to the iamnottheone 03/01/16 01:13:39 PM
#3041   a lot of investors read seeking alpha and iamnottheone 03/01/16 01:10:29 PM
#3040   I found this really great article, seeking iamnottheone 03/01/16 09:23:43 AM
#3039   That is 2 weeks old need y did ttubular 02/23/16 05:44:22 PM
#3038   Rexahn Pharmaceuticals Completes Stage 1 and Begins Enrollment High Stakes Gamble 02/23/16 05:14:58 PM
#3037   What news ttubular 02/23/16 04:52:40 PM
#3036   Hmm... This is REALLY GOOD NEWS Super curious High Stakes Gamble 02/23/16 04:43:32 PM
#3035   Thanks Theo, finally some news...and it's good! gr8f1 02/09/16 01:46:10 PM
#3034   finance.yahoo.com/news/rexahn-pharmaceuticals-completes-stage-1-140000048.h Theo 02/08/16 09:23:54 AM
#3033   Is anyone buying rnn? Any good news Imoutpickinyou 01/27/16 01:56:59 PM
#3032   Agreed, and my apologies on that. I had Spideyboy 12/01/15 08:40:48 AM
#3031   RNN is traded on the NYSE and as DesertBlizzard 12/01/15 12:54:07 AM
#3030   I totally agree with your post. Spideyboy 11/30/15 10:00:06 AM
#3029   You are welcome! Dionna 11/30/15 09:52:21 AM
#3028   Hi Dionna, Spideyboy 11/30/15 09:46:36 AM
#3027   I've been here for over a year and Dionna 11/30/15 08:57:06 AM
#3026   Well cool ,i bailed months ago at 69 Spuds McKenz66 11/29/15 05:52:43 AM
PostSubject